Amgen Research Munich GmbH


    • Company type:
      • Manufacturer
    • Year founded:
    • 1993
    • Employees (at the site):
    • 122
    • Turnover range:
    • 10m - <50m EUR
    • Products/services:
    • Drug Development, Antibody, Immune Therapy, Oncology

    • Core competencies:
    • Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform: BiTETM ('Bispecific T cell engagers'), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drug candidates. The Company has attracted both top-tier life science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc., and Serono.

    • Language skills:
    • German
    • Key Tech / section:
      • Biotechnology: Prophylactic drug development
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72.19: Other research and experimental development on natural sciences and engineering
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Christopher McKinlay (Mr.)
      - Management

      Christophe Bourdon (Mr.)
      - Management

      Evelyn Wolf (Mrs.)
      - Sales / marketing